2026-10-13 12:43:00 UTC#452255newconfirmednews
CRVO stock news
CRVO stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire13 wire items
2026-10-05 11:25:34 UTC#412940newconfirmednews
HC Wainwright reiterates Buy rating on CervoMed with $25 price target
tradingviewimportance 0.40trust 0.70HC Wainwright & Co. +0.20CervoMed Inc. +0.50Neflamapimod +0.50+1 entities
2026-09-28 21:14:03 UTC#380366newconfirmednews
CervoMed unveils 50mg neflamapimod tablet; FDA removes exposure cap to allow 100mg BID dosing
tradingviewimportance 0.60trust 0.80CervoMed Inc. +0.60neflamapimod +0.60Food and Drug Administration +0.60
2026-09-15 21:12:12 UTC#317001duplicateconfirmednews
EIP Pharma (CRVO) advances neflamapimod for dementia with Lewy bodies to Phase III
2026-09-15 20:59:40 UTC#316906newconfirmednews
EIP Pharma (CRVO) advances neflamapimod for dementia with Lewy bodies to Phase III with new formulation
quartrimportance 0.40trust 0.50EIP Pharma, Inc. +0.60neflamapimod +0.60dementia with Lewy bodies +0.50
2026-09-11 16:33:49 UTC#299883duplicateconfirmedanalysis
CervoMed's neflamapimod advances toward Phase III in DLB; PPA and ALS programs targeted for 12-18 month readouts
quartrimportance 0.30trust 0.50CervoMed Inc. +0.40Neflamapimod +0.40Dementia with Lewy bodies +0.30+2 entities
2026-09-11 15:54:47 UTC#299688newconfirmednews
CervoMed readies Phase III trial for neflamapimod in DLB following positive Phase II results
quartrimportance 0.40trust 0.50CervoMed Inc. +0.50neflamapimod +0.50Dementia with Lewy bodies +0.50+2 entities
2026-09-10 11:30:00 UTC#291523newconfirmedpress release
CervoMed Phase 2a neflamapimod data for nfvPPA accepted as late-breaking oral session at ISFTD 2026
globenewswireimportance 0.40trust 0.90CervoMed Inc. +0.40Neflamapimod +0.40International Society of Frontotemporal Dementias 0+2 entities
2026-08-10 11:34:14 UTC#152241newconfirmednews
CervoMed Inc. reports Q2 2026 financial results
2026-08-10 11:00:08 UTC#152149newforecastnews
CervoMed Inc. (CRVO) Q2 2026 Earnings Preview: Expected Revenue $50K, EPS Loss of $0.84
2026-08-07 22:01:42 UTC#147808newconfirmednews
CervoMed Inc. Q2 adjusted loss of $0.64/share beats analyst estimate of $0.87 loss
2026-07-15 10:50:00 UTC#34939newconfirmednews
CervoMed price target maintained at $25.00 by H.C. Wainwright & Co.
2026-07-13 10:25:00 UTC#24868newconfirmednews